- Innovate UK, part of UK Research and Innovation, is investing £10 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to Mestag
- Bispecific antibody MST-0300 is a first-of-its-kind approach designed to conditionally induce tertiary lymphoid structures (TLS) in solid tumors, an exciting new therapeutic strategy with potential to revolutionize cancer treatment
CAMBRIDGE, United Kingdom, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics ("Mestag"), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has been awarded a "Transforming Cancer Therapeutics" grant from Innovate UK's Cancer Therapeutics program of £1.5 million ($1.9 million) to accelerate the development of its MST-0300 antibody.
MST-0300 is a first-in-class bispecific antibody designed to induce TLS in solid tumors in a highly specific and localized fashion. The presence of TLS in tumors has recently emerged as being strongly correlated with improved outcomes for cancer patients across multiple tumor types. TLS are believed to enable improved immune cell access to the tumor and drive local immune cell education, leading to a powerful orchestrated anti-tumor response. Mestag data in hard-to-treat cancer models, recently presented at the 2024 American Association of Cancer Research conference, demonstrate potent anti-tumor effects.
Susan Hill, PhD, Chief Executive Officer of Mestag Therapeutics, said, "We are honored to have been selected as a recipient for this highly competitive translational ...
